Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Law Offices of Howard G. Smith announces that it is investigating whether Allion Healthcare, Inc.'s ("Allion" or the "Company") (NASDAQ: ALLI) directors complied with their...
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Allion Healthcare, Inc. (“Allion” or the “Company”...
Attorney Advertising. Notice is hereby given that Stull, Stull & Brody has commenced an investigation on behalf of shareholders of Allion Healthcare, Inc. (“Allion” or the...
Attorney Advertising. The law firm of Wolf Haldenstein Adler Freeman & Herz LLP is investigating possible breaches of fiduciary duty by the Board of Directors of Allion...
Levi & Korsinsky is investigating the Board of Directors of Allion Healthcare, Inc. (“Allion” or the “Company”) (NasdaqGM: ALLI) for possible breaches of fiduciary duty and...
Allion Healthcare, Inc. (NASDAQ: ALLI) today announced that it has entered into a definitive merger agreement for the Company to be acquired and taken private by an affiliate of...
Allion Healthcare (NASDAQ: ALLI): Second Quarter Highlights Net sales increased 15.3% to $100 million from $86 million Specialty HIV net sales increased 9.4% to $75...
Allion Healthcare, Inc. (NASDAQ: ALLI), today announced that it has entered into a partnership with Being Alive San Diego to launch a Community Learning Center in San Diego...
Allion Healthcare, Inc. (NASDAQ: ALLI), today announced that it will release its financial results for the second quarter ended June 30, 2009, after the close of U.S. financial...
Allion Healthcare (NASDAQ: ALLI): Fully Diluted EPS Guidance increased to $0.50 to $ 0.52 per share Net sales increased 48% to $96.6 million from $65.3 million Net...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
